Literature DB >> 28946553

Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma.

Jian Chen1, Li Yang2, Xiongwei Wang1.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) have been demonstrated to play an important role in the development and progression of various types of cancer including glioblastoma (GBM).
OBJECTIVE: The aim of this study was to investigate the expression pattern and prognostic significance of serum miR-203 in patients with GBM.
METHODS: miR-203 extracted from cell culture medium and serum samples was detected by real-time PCR. The correlation between serum miR-203 expression as well as clinicopathological characteristics and patient survival was determined.
RESULTS: The expression level of miR-203 was remarkably reduced in the GBM cells and their culture medium. Serum miR-203 expression was significantly decreased in GBM patients compared with low grade glioma (LGG) patients and healthy controls. In addition, serum miR-203 discriminated GBM patients from LGG patients and healthy subjects. Chi-squared analysis showed that a significant correlation was found between low serum miR-203 expression and larger tumor size as well as lower Karnofsky Performance Scale scores. Patients with lower serum miR-203 suffered poorer overall survival (OS) and progression free survival (PFS). Multivariate analysis indicated that low miR-203 expression is an independent prognostic factor for poor OS in GBM patients.
CONCLUSIONS: These data demonstrate that serum miR-203 expression might serve as a potential prognostic indicator of GBM.

Entities:  

Keywords:  Glioblastoma; miR-203; prognosis; real-time PCR

Mesh:

Substances:

Year:  2017        PMID: 28946553     DOI: 10.3233/CBM-170335

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

1.  Downregulated miR-203 attenuates IL-β, IL-6, and TNF-α activation in TRAF6-treated human renal mesangial and tubular epithelial cells.

Authors:  Li Zhang; Xingkun Zhang
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

Review 2.  MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta-analysis.

Authors:  Qian Zhou; Jing Liu; Jing Quan; Wenlan Liu; Hui Tan; Weiping Li
Journal:  Cancer Sci       Date:  2018-08-03       Impact factor: 6.716

Review 3.  MicroRNA based theranostics for brain cancer: basic principles.

Authors:  George E D Petrescu; Alexandru A Sabo; Ligia I Torsin; George A Calin; Mihnea P Dragomir
Journal:  J Exp Clin Cancer Res       Date:  2019-05-29

4.  Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia.

Authors:  Yingmeng Guo
Journal:  Bioengineered       Date:  2019-12       Impact factor: 3.269

5.  MiR-29a Inhibits Glioma Tumorigenesis through a Negative Feedback Loop of TRAF4/Akt Signaling.

Authors:  Yongjie Liu; Naiquan Duan; Shibo Duan
Journal:  Biomed Res Int       Date:  2018-08-14       Impact factor: 3.411

6.  miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1.

Authors:  Yang Meng; Xiaoyan Hu; Shasha Li; Xinyi Zeng; Lei Qiu; Mingtian Wei; Ziqing Wang; Junhong Han
Journal:  BMC Cancer       Date:  2020-10-27       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.